Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time_老虎社区_美港股上老虎

Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time

Seeking Alpha2021-08-10

According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

YiiYii
·2021-08-11
[惊讶]
回复
1
举报
收起
- YiiYii:
  [财迷]
  2021-08-11
  回复
  举报
WilliamTeo
·2021-08-10
Pro
回复
点赞
举报
GG21
·2021-08-10
Tell me your opinion about this news...
回复
1
举报
DingDang
·2021-08-10
Go jab them!! Please like and comment!
回复
2
举报
Dawang
·2021-08-10
1 dosage 100 mcg versus 30mcg from pfizer
回复
7
举报
收起
- koolgal回复Dawang:
  Vaccine shot.
  2021-08-16
  回复
  举报
- Dawang:
  u mean the vaccine shot, or the stock? different answers... 😂😂😂
  2021-08-16
  回复
  举报
- koolgal:
  Which do you prefer?
  2021-08-16
  回复
  举报
Anonymous2
·2021-08-10
Like please
回复
4
举报
收起
- Siewleerocks:
  Ok
  2021-08-10
  回复
  举报
jeffmum
·2021-08-10
Good one
回复
6
举报
meowmeow88
·2021-08-10
Wonde why. Both are the same technology and should be the same
回复
2
举报
收起
- edgetrader:
  Share price movement not the same
  2021-08-10
  回复
  举报
Jinkachu
·2021-08-10
Like and comment
回复
4
举报
收起
- jeffmum:
  ok
  2021-08-10
  回复
  举报
Huatkia168
·2021-08-10
Interesting
回复
6
举报
收起
- Anonymous2:
  Yeah
  2021-08-10
  回复
  举报
EdwardKarchi
·2021-08-10
Please like and comment
回复
7
举报
收起
- adarwitan:
  Done. Pls like and comment too, if not will remove
  2021-08-10
  回复
  举报
- Jinkachu:
  like and comment
  2021-08-10
  回复
  举报
Jjjjia
·2021-08-10
Pls like
回复
7
举报
收起
- EdwardKarchi:
  Done
  2021-08-10
  回复
  举报
Jjjjia
·2021-08-10
Pls like
回复
6
举报
zcml
·2021-08-10
Pls help to like thanks
回复
10
举报
收起
- koolgal:
  👍😊
  2021-09-08
  回复
  举报
hwhw123
·2021-08-10
Yes
回复
9
举报
收起
- Sporepuppy:
  EXhange like and comment
  2021-08-10
  回复
  举报
- ericokh:
  like pls
  2021-08-10
  回复
  举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-08-10 16:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122891084","market":"us","top_or_hot":-1,"title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time","media":"Seeking Alpha","content":"<div>\n<p>According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters ...</p>\n\n<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 16:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters ...</p>\n\n<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","article_id":"1122891084","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","pubTimestamp":1628585720,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"translate_title":"现代新冠肺炎疫苗可能比辉瑞对抗德尔塔变异毒株更好；突破性案件随时间上升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9},"content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","kind":"news","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[{"id":892357449,"gmtCreate":1628640769281,"gmtModify":1633745530811,"author":{"id":"3567052123559984","authorId":"3567052123559984","name":"YiiYii","avatar":"https://static.tigerbbs.com/bb10d436567743e0e60ba0933900bf20","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3567052123559984","authorIdStr":"3567052123559984"},"htmlText":"[惊讶]&nbsp;","listText":"[惊讶]&nbsp;","text":"[惊讶]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/892357449","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5488540,"gmtCreate":1628640835755,"gmtModify":1635154807519,"authorId":3567052123559984,"author":{"id":3567052123559984,"idStr":"3567052123559984","authorId":3567052123559984,"name":"YiiYii","avatar":"https://static.tigerbbs.com/bb10d436567743e0e60ba0933900bf20","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":892357449,"type":1,"supId":0,"prevId":0,"content":"[财迷]","text":"[财迷]","html":"[财迷]"}],"langContent":"CN"},{"id":896406617,"gmtCreate":1628598943439,"gmtModify":1631892264519,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"htmlText":"Pro","listText":"Pro","text":"Pro","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896406617","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":896583299,"gmtCreate":1628593654011,"gmtModify":1633745906529,"author":{"id":"3578365762999468","authorId":"3578365762999468","name":"GG21","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3578365762999468","authorIdStr":"3578365762999468"},"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896583299","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":896504266,"gmtCreate":1628590243855,"gmtModify":1633745926462,"author":{"id":"3553254172092293","authorId":"3553254172092293","name":"DingDang","avatar":"https://static.tigerbbs.com/d2a0c38ce6f3c2661fa15b7d1f52eeaf","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3553254172092293","authorIdStr":"3553254172092293"},"htmlText":"Go jab them!! Please like and comment!","listText":"Go jab them!! Please like and comment!","text":"Go jab them!! Please like and comment!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896504266","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":896278540,"gmtCreate":1628588969280,"gmtModify":1631888876154,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3579482809178950","authorIdStr":"3579482809178950"},"htmlText":"1 dosage 100 mcg versus 30mcg from pfizer","listText":"1 dosage 100 mcg versus 30mcg from pfizer","text":"1 dosage 100 mcg versus 30mcg from pfizer","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/896278540","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5543793,"gmtCreate":1629111700398,"gmtModify":1631888876188,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"currentWearingBadge":{"badgeId":"99a38ff64bfd44f891fd016771fc8f64-1","templateUuid":"99a38ff64bfd44f891fd016771fc8f64","name":"超级披露者","description":"在交易分享中开启超级披露","bigImgUrl":"https://static.tigerbbs.com/802f4014829adb4e63332fc230b97e42","smallImgUrl":"https://static.tigerbbs.com/70e97d213ed3e4f4820224f1366d402f","redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://www.itigerup.com/activity/forapp/star-investor","redirectLinkValidityFrom":1776816000000,"redirectLinkValidityTo":2156198400000,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.23","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1104,"isScarce":1,"effectEnabled":0,"wearingSort":1},"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[{"categoryType":1104,"badgeId":"99a38ff64bfd44f891fd016771fc8f64-1","name":"超级披露者","description":"在交易分享中开启超级披露","smallImgUrl":"https://static.tigerbbs.com/70e97d213ed3e4f4820224f1366d402f","bigImgUrl":"https://static.tigerbbs.com/802f4014829adb4e63332fc230b97e42","isScarce":1,"plateColors":{"bgColor":{"dark":"#2f2a1f","tint":"#fcf6e5"},"fontColor":{"dark":"#dea95e","tint":"#885600"}},"effectEnabled":0,"redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://www.itigerup.com/activity/forapp/star-investor","redirectLinkValidityFrom":1776816000000,"redirectLinkValidityTo":2156198400000,"sortingWeight":0,"wearable":1}]},"repliedAuthorId":3579482809178950,"repliedAuthor":{"id":3579482809178950,"idStr":"3579482809178950","authorId":3579482809178950,"name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"objectId":896278540,"type":1,"supId":5536876,"prevId":5543750,"content":"Vaccine shot.","text":"Vaccine shot.","html":"Vaccine shot."},{"id":5543750,"gmtCreate":1629111301342,"gmtModify":1631888876176,"authorId":3579482809178950,"author":{"id":3579482809178950,"idStr":"3579482809178950","authorId":3579482809178950,"name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":896278540,"type":1,"supId":5536876,"prevId":0,"content":"u mean the vaccine shot, or the stock? different answers... 😂😂😂","text":"u mean the vaccine shot, or the stock? different answers... 😂😂😂","html":"u mean the vaccine shot, or the stock? different answers... 😂😂😂"},{"id":5536876,"gmtCreate":1629064081672,"gmtModify":1631888876158,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"currentWearingBadge":{"badgeId":"99a38ff64bfd44f891fd016771fc8f64-1","templateUuid":"99a38ff64bfd44f891fd016771fc8f64","name":"超级披露者","description":"在交易分享中开启超级披露","bigImgUrl":"https://static.tigerbbs.com/802f4014829adb4e63332fc230b97e42","smallImgUrl":"https://static.tigerbbs.com/70e97d213ed3e4f4820224f1366d402f","redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://www.itigerup.com/activity/forapp/star-investor","redirectLinkValidityFrom":1776816000000,"redirectLinkValidityTo":2156198400000,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.23","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1104,"isScarce":1,"effectEnabled":0,"wearingSort":1},"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[{"categoryType":1104,"badgeId":"99a38ff64bfd44f891fd016771fc8f64-1","name":"超级披露者","description":"在交易分享中开启超级披露","smallImgUrl":"https://static.tigerbbs.com/70e97d213ed3e4f4820224f1366d402f","bigImgUrl":"https://static.tigerbbs.com/802f4014829adb4e63332fc230b97e42","isScarce":1,"plateColors":{"bgColor":{"dark":"#2f2a1f","tint":"#fcf6e5"},"fontColor":{"dark":"#dea95e","tint":"#885600"}},"effectEnabled":0,"redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://www.itigerup.com/activity/forapp/star-investor","redirectLinkValidityFrom":1776816000000,"redirectLinkValidityTo":2156198400000,"sortingWeight":0,"wearable":1}]},"repliedAuthorId":0,"objectId":896278540,"type":1,"supId":0,"prevId":0,"content":"Which do you prefer?","text":"Which do you prefer?","html":"Which do you prefer?"}],"langContent":"EN"},{"id":896278273,"gmtCreate":1628588946192,"gmtModify":1631889807780,"author":{"id":"3560247957239615","authorId":"3560247957239615","name":"Anonymous2","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3560247957239615","authorIdStr":"3560247957239615"},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/896278273","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5482495,"gmtCreate":1628589562074,"gmtModify":1635155297829,"authorId":3578472165464903,"author":{"id":3578472165464903,"idStr":"3578472165464903","authorId":3578472165464903,"name":"Siewleerocks","avatar":"https://static.tigerbbs.com/f00504e0b6e3e8236e593d86c0ce08ed","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":896278273,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":896270320,"gmtCreate":1628588596660,"gmtModify":1631883894945,"author":{"id":"3582787548532316","authorId":"3582787548532316","name":"jeffmum","avatar":"https://static.tigerbbs.com/3aaf38ada4e9468a5ba38839ff3b40a9","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3582787548532316","authorIdStr":"3582787548532316"},"htmlText":"Good one","listText":"Good one","text":"Good one","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896270320","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":896270941,"gmtCreate":1628588592283,"gmtModify":1633745935232,"author":{"id":"4091674547333280","authorId":"4091674547333280","name":"meowmeow88","avatar":"https://static.tigerbbs.com/b9e0c95f88993b5f06fcd816677a1a2f","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"4091674547333280","authorIdStr":"4091674547333280"},"htmlText":"Wonde why. Both are the same technology and should be the same","listText":"Wonde why. Both are the same technology and should be the same","text":"Wonde why. Both are the same technology and should be the same","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/896270941","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5483622,"gmtCreate":1628598403596,"gmtModify":1635155224948,"authorId":3570751249933438,"author":{"id":3570751249933438,"idStr":"3570751249933438","authorId":3570751249933438,"name":"edgetrader","avatar":"https://static.tigerbbs.com/7d0e920d94a7891f4c6393f3e5510ccc","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":896270941,"type":1,"supId":0,"prevId":0,"content":"Share price movement not the same","text":"Share price movement not the same","html":"Share price movement not the same"}],"langContent":"EN"},{"id":896243343,"gmtCreate":1628587885782,"gmtModify":1633745939364,"author":{"id":"3569530406935035","authorId":"3569530406935035","name":"Jinkachu","avatar":"https://static.tigerbbs.com/a47cb60ff4f5df9c8eac85aa6198baa0","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3569530406935035","authorIdStr":"3569530406935035"},"htmlText":"Like and comment&nbsp;","listText":"Like and comment&nbsp;","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/896243343","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5482371,"gmtCreate":1628588639727,"gmtModify":1635155305512,"authorId":3582787548532316,"author":{"id":3582787548532316,"idStr":"3582787548532316","authorId":3582787548532316,"name":"jeffmum","avatar":"https://static.tigerbbs.com/3aaf38ada4e9468a5ba38839ff3b40a9","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":896243343,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":896240838,"gmtCreate":1628587719824,"gmtModify":1631891380269,"author":{"id":"3551331974959956","authorId":"3551331974959956","name":"Huatkia168","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3551331974959956","authorIdStr":"3551331974959956"},"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/896240838","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5482427,"gmtCreate":1628588956393,"gmtModify":1631891380266,"authorId":3560247957239615,"author":{"id":3560247957239615,"idStr":"3560247957239615","authorId":3560247957239615,"name":"Anonymous2","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":896240838,"type":1,"supId":0,"prevId":0,"content":"Yeah","text":"Yeah","html":"Yeah"}],"langContent":"EN"},{"id":896255147,"gmtCreate":1628587464089,"gmtModify":1633745942104,"author":{"id":"3578819428738173","authorId":"3578819428738173","name":"EdwardKarchi","avatar":"https://static.tigerbbs.com/8393250f23521cbb5d95b0a87f3f846f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3578819428738173","authorIdStr":"3578819428738173"},"htmlText":"Please like and comment&nbsp;","listText":"Please like and comment&nbsp;","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/896255147","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5482212,"gmtCreate":1628587567668,"gmtModify":1635155317298,"authorId":3584621187072900,"author":{"id":3584621187072900,"idStr":"3584621187072900","authorId":3584621187072900,"name":"adarwitan","avatar":"https://static.tigerbbs.com/2e1efc815108940f96249adf530f9ee9","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":896255147,"type":1,"supId":0,"prevId":0,"content":"Done. Pls like and comment too, if not will <u>remove</u>","text":"Done. Pls like and comment too, if not will <u>remove</u>","html":"Done. Pls like and comment too, if not will <u>remove</u>"},{"id":5482250,"gmtCreate":1628587876855,"gmtModify":1635155315110,"authorId":3569530406935035,"author":{"id":3569530406935035,"idStr":"3569530406935035","authorId":3569530406935035,"name":"Jinkachu","avatar":"https://static.tigerbbs.com/a47cb60ff4f5df9c8eac85aa6198baa0","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":896255147,"type":1,"supId":0,"prevId":0,"content":"like and comment","text":"like and comment","html":"like and comment"}],"langContent":"EN"},{"id":896227548,"gmtCreate":1628586793084,"gmtModify":1633745945927,"author":{"id":"4087709618925430","authorId":"4087709618925430","name":"Jjjjia","avatar":"https://static.tigerbbs.com/25215d9b4b22838734cba07948cafe46","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"4087709618925430","authorIdStr":"4087709618925430"},"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/896227548","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5482200,"gmtCreate":1628587479645,"gmtModify":1635155318139,"authorId":3578819428738173,"author":{"id":3578819428738173,"idStr":"3578819428738173","authorId":3578819428738173,"name":"EdwardKarchi","avatar":"https://static.tigerbbs.com/8393250f23521cbb5d95b0a87f3f846f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":896227548,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"},{"id":896227804,"gmtCreate":1628586762708,"gmtModify":1633745946050,"author":{"id":"4087709618925430","authorId":"4087709618925430","name":"Jjjjia","avatar":"https://static.tigerbbs.com/25215d9b4b22838734cba07948cafe46","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"4087709618925430","authorIdStr":"4087709618925430"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896227804","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":896228120,"gmtCreate":1628586207060,"gmtModify":1631890858176,"author":{"id":"4088490026197220","authorId":"4088490026197220","name":"zcml","avatar":"https://static.tigerbbs.com/282fc713a264eae65e8d4ae7f74b3395","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"4088490026197220","authorIdStr":"4088490026197220"},"htmlText":"Pls help to like thanks","listText":"Pls help to like thanks","text":"Pls help to like thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/896228120","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5792162,"gmtCreate":1631093464961,"gmtModify":1631890858174,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"currentWearingBadge":{"badgeId":"99a38ff64bfd44f891fd016771fc8f64-1","templateUuid":"99a38ff64bfd44f891fd016771fc8f64","name":"超级披露者","description":"在交易分享中开启超级披露","bigImgUrl":"https://static.tigerbbs.com/802f4014829adb4e63332fc230b97e42","smallImgUrl":"https://static.tigerbbs.com/70e97d213ed3e4f4820224f1366d402f","redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://www.itigerup.com/activity/forapp/star-investor","redirectLinkValidityFrom":1776816000000,"redirectLinkValidityTo":2156198400000,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.23","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1104,"isScarce":1,"effectEnabled":0,"wearingSort":1},"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[{"categoryType":1104,"badgeId":"99a38ff64bfd44f891fd016771fc8f64-1","name":"超级披露者","description":"在交易分享中开启超级披露","smallImgUrl":"https://static.tigerbbs.com/70e97d213ed3e4f4820224f1366d402f","bigImgUrl":"https://static.tigerbbs.com/802f4014829adb4e63332fc230b97e42","isScarce":1,"plateColors":{"bgColor":{"dark":"#2f2a1f","tint":"#fcf6e5"},"fontColor":{"dark":"#dea95e","tint":"#885600"}},"effectEnabled":0,"redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://www.itigerup.com/activity/forapp/star-investor","redirectLinkValidityFrom":1776816000000,"redirectLinkValidityTo":2156198400000,"sortingWeight":0,"wearable":1}]},"repliedAuthorId":0,"objectId":896228120,"type":1,"supId":0,"prevId":0,"content":"👍😊","text":"👍😊","html":"👍😊"}],"langContent":"EN"},{"id":896220114,"gmtCreate":1628585787738,"gmtModify":1633745950758,"author":{"id":"3578710390898389","authorId":"3578710390898389","name":"hwhw123","avatar":"https://static.tigerbbs.com/d8403e7374bdcb179a82aff3b6d9338e","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"idStr":"3578710390898389","authorIdStr":"3578710390898389"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/896220114","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohunote.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠肺炎疫苗对抗德尔塔变异毒株可能比辉瑞更好；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>  <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>  <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>  <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>  <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>  <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>  <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>  <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>  <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>  <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>  <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>  <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>  <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>  <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项研究尚未经过同行评审，包括梅奥诊所医疗系统的50,000多名患者。</li><li>研究人员发现，Moderna 的 Covid-19 疫苗的有效性从 2021 年初的 86% 下降到 7 月份的 76%（当时德尔塔变异毒株占主导地位）。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在防止Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要注射Moderna加强针。</li><li>在另一项研究中，安大略省的老年养老院居民在接种Moderna疫苗后比接种辉瑞/BioNTech疫苗后产生了更强的免疫反应，特别是对变异的免疫反应。</li><li>辉瑞公司发言人表示：“我们仍然相信……在完全接种疫苗后的 6 至 12 个月内，可能需要接种第三剂加强剂，以维持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性的新冠肺炎几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，其中包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测阳性的几率较高。</li><li>在60岁以上的患者中，当第二剂后146天过去时，阳性测试的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”合著者、以色列 Leumit Health Services 的 Eugene Merzon 博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5481981,"gmtCreate":1628585973403,"gmtModify":1635155332063,"authorId":4089501973615070,"author":{"id":4089501973615070,"idStr":"4089501973615070","authorId":4089501973615070,"name":"Sporepuppy","avatar":"https://static.tigerbbs.com/caf34258aff8afe478620b82647f1199","vip":2,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":896220114,"type":1,"supId":0,"prevId":0,"content":"EXhange like and comment ","text":"EXhange like and comment ","html":"EXhange like and comment "},{"id":5482101,"gmtCreate":1628586764688,"gmtModify":1635155324157,"authorId":3560402226461385,"author":{"id":3560402226461385,"idStr":"3560402226461385","authorId":3560402226461385,"name":"ericokh","avatar":"https://static.tigerbbs.com/4b5f2c2754be94d2d5444fafc4c7ccbc","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":896220114,"type":1,"supId":0,"prevId":0,"content":"like pls","text":"like pls","html":"like pls"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":55,"commentSize":15,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}